Announcements Trials
Browse Landscape

Status

Recruiting 2

Sponsor Class

INDUSTRY 2

Study Type

Interventional 15Observational 2

Sponsor

Cancer Type

Thoracic 1

Conditions

Neoplasms 287Breast Neoplasms 280Lung Neoplasms 134Prostatic Neoplasms 125Colorectal Neoplasms 113Carcinoma, Non-Small-Cell Lung 109Pancreatic Neoplasms 73Carcinoma, Hepatocellular 56Stomach Neoplasms 54Hematologic Neoplasms 53Brain Neoplasms 53Ovarian Neoplasms 52Urinary Bladder Neoplasms 49Multiple Myeloma 49Leukemia, Myeloid, Acute 48Esophageal Neoplasms 47Melanoma 46Disease 43Head and Neck Neoplasms 40Colonic Neoplasms 40Rectal Neoplasms 37Liver Neoplasms 37Precursor Cell Lymphoblastic Leukemia-Lymphoma 36Neoplasm Metastasis 36Lymphoma 33Uterine Cervical Neoplasms 32Endometrial Neoplasms 32Leukemia, Lymphocytic, Chronic, B-Cell 31Thyroid Neoplasms 29Recurrence 29

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Observational × Hereditary Sensory and Autonomic Neuropathies × 90 days × Clear all
NCT06494540 2026-05-22

NAUTIC

AstraZeneca

Recruiting
600 enrolled
Thoracic

Carcinoma, Non-Small-Cell Lung, Hereditary Sensory and Autonomic Neuropathies

NCT05868629 2026-04-01

Clinical Study To Further Evaluate The Efficacy Of Dabrafenib Plus Trametinib In Patients With Rare BRAF V600E Mutation-Positive Unresectable or Metastatic Solid Tumors

Novartis

Recruiting
40 enrolled

Hereditary Sensory and Autonomic Neuropathies

Data powered by HemOnc (CC BY 4.0) Colophon âš¡